Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

378
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
378
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

511
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
511
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
Acute Respiratory Failure-V01:29

Acute Respiratory Failure-V

123
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
123

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-COVID paediatric dysautonomia: never the heart, always the brain-myth or maxim?

Cardiology in the young·2026
Same author

Heart Transplant Outcomes in Chemotherapy-Induced vs. Non-Ischemic-Dilated Cardiomyopathy: Pediatric and Adult Recipients in the Ventricular Assist Device Era.

Reviews in cardiovascular medicine·2026
Same author

Pediatric Myocarditis: Challenges in Diagnosis and Treatment.

Paediatric drugs·2026
Same author

Pediatric Heart Failure Pharmacotherapy: Transformative Insights for the Future.

Reviews in cardiovascular medicine·2025
Same author

Mechanism and Treatment of Right Ventricular Failure Due to Pulmonary Hypertension in Children.

Children (Basel, Switzerland)·2025
Same author

A Systematic Review and Meta-Analysis of the Safety and Efficacy of SGLT2 Inhibitors in Chronic Heart Failure in ACHD Patients.

American journal of cardiovascular drugs : drugs, devices, and other interventions·2024

Related Experiment Video

Updated: Jun 1, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.3K

Novel Therapies for Right Ventricular Failure.

Bibhuti B Das1

  • 1Pediatric Advanced Heart Failure and Heart Transplant Program, University of Mississippi Medical Center, 2500 N State Street, Jackson, MS, USA. bbdas001@gmail.com.

Current Cardiology Reports
|January 18, 2025
PubMed
Summary

New therapies show promise for right ventricular failure (RVF), a serious condition often resistant to traditional treatments. Research is exploring novel drugs and approaches to improve outcomes for patients with RVF, particularly when linked to left heart failure.

Keywords:
Durable RVADPulmonary hypertensionRight heart failureRight ventricular failureTemporary RVAD

More Related Videos

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

10.4K
Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice
10:18

Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice

Published on: February 1, 2022

3.0K

Related Experiment Videos

Last Updated: Jun 1, 2025

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.3K
Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
09:40

Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice

Published on: May 13, 2019

10.4K
Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice
10:18

Generation and Characterization of Right Ventricular Myocardial Infarction Induced by Permanent Ligation of the Right Coronary Artery in Mice

Published on: February 1, 2022

3.0K

Area of Science:

  • Cardiovascular Medicine
  • Pulmonary Hypertension Research
  • Translational Cardiology

Background:

  • Right ventricular failure (RVF) is a significant complication of cardiac and pulmonary disorders with a poor prognosis.
  • Current treatments for RVF are limited, with strategies effective for left ventricular failure showing less success.
  • Understanding RVF mechanisms is crucial for developing targeted therapies.

Purpose of the Study:

  • To review contemporary and novel therapies for right ventricular failure (RVF).
  • To explore the potential of emerging heart failure treatments in managing RVF.
  • To highlight the need for a deeper understanding of RVF pathophysiology.

Main Methods:

  • Review of current literature on right ventricular failure treatments.
  • Exploration of contemporary heart failure therapies (e.g., ARNI, SGLT2i, sGC stimulators).
  • Examination of novel pharmacological and device-centered interventions in preclinical studies.

Main Results:

  • Emerging therapies targeting metabolism, calcium homeostasis, oxidative stress, and inflammation show preclinical promise for RVF.
  • Interest is growing in epigenetic modifications as potential therapeutic targets for RVF.
  • Novel pharmacological and cell-based options are being developed, aligning with precision medicine.

Conclusions:

  • Contemporary therapies, including angiotensin receptor and neprilysin inhibitors, SGLT2 inhibitors, and sGC stimulators, may benefit RVF, especially when co-existing with left heart failure.
  • Preclinical studies indicate novel interventions targeting various cellular pathways hold promise for RVF treatment.
  • Further research into RVF mechanisms is essential for advancing precision medicine approaches and developing effective therapies.